[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338927-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338927-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeted-demethylation-and-activation-of-nlrc5-augment-cancer-immunogenicity-through-mhc-class-i","Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I","","Impaired MHC class I expression is a key immune-evasion mechanism in cancers and limits responses to checkpoint blockade, yet specific ways to induce MHC class I remain limited. This study presents TRED-I, a CRISPR/Cas9-based gene-specific system that targets NLRC5 via a demethylation enzyme and transcriptional activators. TRED-I increases MHC class I antigen presentation, accelerates CD8+ T-cell activation, and suppresses tumors in animal models with improved anti–PD-1 efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeted-demethylation-and-activation-of-nlrc5-augment-cancer-immunogenicity-through-mhc-class-i/338927/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeted-demethylation-and-activation-of-nlrc5-augment-cancer-immunogenicity-through-mhc-class-i/338927.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in cancer immunotherapy?","Question",{"text":63,"@type":64},"The study addresses immune evasion caused by impaired or downregulated MHC class I in cancers, which is associated with poor prognosis and resistance to checkpoint blockade therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the TRED-I system work?",{"text":68,"@type":64},"TRED-I is a modified CRISPR/Cas9-based, gene-specific system that targets the NLRC5 promoter and recruits a demethylating enzyme plus transcriptional activators to increase MHC class I antigen presentation and CD8+ T-cell activation.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic impact did TRED-I show in animal cancer models?",{"text":72,"@type":64},"In an animal cancer model, introducing TRED-I produced tumor-suppressive effects accompanied by increased infiltration and activation of CD8+ T cells, and it boosted the efficacy of anti–PD-1 checkpoint blockade therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338927,1790156721,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","RESEARCH ARTICLE  \nIMMUNOLOGY AND INFLAMMATION  \nTargeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I  \nXin Suna , Toshiyuki Watanabea, Yoshitaka Odab, Weidong Shenc, Alaa Ahmada, Ryota Oudaa, Paul de Figueiredod,e,f,g, Hidemitsu Kitamurac, h , Shinya Tanakab, i, and Koichi S. Kobayashia,d,j,1  \nEdited by Diane Mathis, Harvard Medical School, Boston, MA; received June 29, 2023; accepted December 30, 2023  \nImpaired expression of MHC (major histocompatibility complex) class I in cancers constitutes a major mechanism of immune evasion. It has been well documented that the low level of MHC class I is associated with poor prognosis and resistance to checkpoint blockade therapies. However, there is lmited approaches to specifically induce MHC class I to date. Here, we show an approach for robust and specific induction of MHC class I by targeting an MHC class I transactivator (CITA)/NLRC5, using a CRISPR/Cas9-based gene-specific system, designated TRED-I (Targeted reactivation and demethylation for MHC-I). The TRED-I system specifically recruits a demethylating enzyme and transcriptional activators on the NLRC5 promoter, driving increased MHC class I antigen presentation and accelerated CD8+ T cell activation. Introduction ofthe TRED-I system in an animal cancer model exhibited tumor-suppressive effects accompanied with increased infiltration and activation of CD8+ T cells. Moreover, this approach boosted the efficacy of checkpoint blockade therapy using anti-PD1 (programmed cell death protein) antibody. Therefore, targeting NLRC5 by this strategy provides an attractive therapeutic approach for cancer.  \ncancer immunotherapy | antigen presentation | immune checkpoint blockade | MHC-I | epigenetic modification  \nAntigen presentation through MHC class I is critical for recognition and eradication of cancers by CD8+ T cells. While cytotoxic CD8+ T cells are equipped with strong tumor-killing activity through cytotoxic molecules such as perforin or granzymes (1), cancer cells evolve to evade CD8+ T cell–mediated anticancer immunity by various strategies for successful survival, replication, and growth (2) . Downregulation of MHC class I gene expression is one of the major immune evasion mechanisms observed in cancer (3) . Moreover, the efficacy of immune checkpoint blockade (ICB) therapy, such as anti-PD-1 therapy, is only 20 ~ 30%, and the impaired MHC class I expression is considered as oneof the major mechanisms underlying this resistance (4–10) .  \nAn MHC class I transactivator (CITA), NLRC5, functions as a master transcriptional regulator of MHC class I and related genes (11, 12) . Genetic and epigenetic alteration of NLRC5 is associated with cancer immune evasion and reduced responses to ICB therapy. NLRC5 interacts with multiple transcription factors on the promoters of MHC class I and related genes and generates the large protein/DNA complex termed the MHC class I enhanceosome complex, which transcriptionally activates genes encoding MHC class I and other key molecules, including proteasome, transporter, and MHC class I subunit B2M (13) . Nlrc5 deletion causes reduced expression of MHC class I and related genes and impaired CD8+ T cell–mediated killing of target cells in mice (14–17) . In cancer patients, the expression level of NLRC5 is positively correlated with MHC class I expression and patients’ prognosis (18). Additionally, the expression level of NLRC5 in cancer patients is positively correlated with responsiveness to anti-PD-1 therapy (19). The NLRC5 promoter is frequently and aberrantly methylated in various cancers (18) . The DNA methylation level of the NLRC5 promoter is negatively correlated with expression levels of NLRC5, MHC class I genes, and patients’ prognosis (18). Although demethylation of the NLRC5 promoter is an attractive therapeutic target to enhance host anticancer immunity by upregulation of the expression of NLRC5 and MHC class I genes, existing DNA demethyla","cbCaigEgs2ltD5eS","https://ap.wps.com/l/cbCaigEgs2ltD5eS","pdf",3370551,11,"English","# Introduction\n## NLRC5 as a master regulator of MHC-I\n## Demethylation as a therapeutic concept\n# Study design and TRED-I system\n# Significance","[{\"question\":\"What problem does the study address in cancer immunotherapy?\",\"answer\":\"The study addresses immune evasion caused by impaired or downregulated MHC class I in cancers, which is associated with poor prognosis and resistance to checkpoint blockade therapies.\"},{\"question\":\"How does the TRED-I system work?\",\"answer\":\"TRED-I is a modified CRISPR/Cas9-based, gene-specific system that targets the NLRC5 promoter and recruits a demethylating enzyme plus transcriptional activators to increase MHC class I antigen presentation and CD8+ T-cell activation.\"},{\"question\":\"What therapeutic impact did TRED-I show in animal cancer models?\",\"answer\":\"In an animal cancer model, introducing TRED-I produced tumor-suppressive effects accompanied by increased infiltration and activation of CD8+ T cells, and it boosted the efficacy of anti–PD-1 checkpoint blockade therapy.\"}]","Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I | PDF",1790026577,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8759777add17c80f910e319410bb4a5.webp",983,1316,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ca05ee2ea019919327b3f319a4d6a5f.webp",982,1315,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f8cda225d959eb7704cff3d418d8b28.webp",981,1313,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fca0029f64e5f2b44aeb7c079668dd2a.webp",980,1312]